Prognostic effect of body mass index in patients with advanced NSCLC treated with chemoimmunotherapy combinations
© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ..
INTRODUCTION: It has been recognized that increasing body mass index (BMI) is associated with improved outcome from immune checkpoint inhibitors (ICIs) in patients with various malignancies including non-small cell lung cancer (NSCLC). However, it is unclear whether baseline BMI may influence outcomes from first-line chemoimmunotherapy combinations.
METHODS: In this international multicenter study, we evaluated the association between baseline BMI, progression-free survival (PFS) and overall survival (OS) in a cohort of patients with stage IV NSCLC consecutively treated with first-line chemoimmunotherapy combinations. BMI was categorized according to WHO criteria.
RESULTS: Among the 853 included patients, 5.3% were underweight; 46.4% were of normal weight; 33.8% were overweight; and 14.5% were obese. Overweight and obese patients were more likely aged ≥70 years (p=0.00085), never smokers (p<0.0001), with better baseline Eastern Cooperative Oncology Group-Performance Status (p=0.0127), and had lower prevalence of central nervous system (p=0.0002) and liver metastases (p=0.0395). Univariable analyses showed a significant difference in the median OS across underweight (15.5 months), normal weight (14.6 months), overweight (20.9 months), and obese (16.8 months) patients (log-rank: p=0.045, log rank test for trend: p=0.131), while no difference was found with respect to the median PFS (log-rank for trend: p=0.510). Neither OS nor PFS was significantly associated with baseline BMI on multivariable analysis.
CONCLUSIONS: In contrast to what was observed in the context of chemotherapy-free ICI-based regimens, baseline BMI does not affect clinical outcomes from chemoimmunotherapy combinations in patients with advanced NSCLC.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:10 |
|---|---|
| Enthalten in: |
Journal for immunotherapy of cancer - 10(2022), 2 vom: 01. Feb. |
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Themen: |
Immune Checkpoint Inhibitors |
|---|
| Anmerkungen: |
Date Completed 29.03.2022 Date Revised 29.03.2022 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1136/jitc-2021-004374 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM337049572 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM337049572 | ||
| 003 | DE-627 | ||
| 005 | 20231225233529.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1136/jitc-2021-004374 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1123.xml |
| 035 | |a (DE-627)NLM337049572 | ||
| 035 | |a (NLM)35173031 | ||
| 035 | |a (PII)e004374 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Cortellini, Alessio |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Prognostic effect of body mass index in patients with advanced NSCLC treated with chemoimmunotherapy combinations |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 29.03.2022 | ||
| 500 | |a Date Revised 29.03.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. | ||
| 520 | |a INTRODUCTION: It has been recognized that increasing body mass index (BMI) is associated with improved outcome from immune checkpoint inhibitors (ICIs) in patients with various malignancies including non-small cell lung cancer (NSCLC). However, it is unclear whether baseline BMI may influence outcomes from first-line chemoimmunotherapy combinations | ||
| 520 | |a METHODS: In this international multicenter study, we evaluated the association between baseline BMI, progression-free survival (PFS) and overall survival (OS) in a cohort of patients with stage IV NSCLC consecutively treated with first-line chemoimmunotherapy combinations. BMI was categorized according to WHO criteria | ||
| 520 | |a RESULTS: Among the 853 included patients, 5.3% were underweight; 46.4% were of normal weight; 33.8% were overweight; and 14.5% were obese. Overweight and obese patients were more likely aged ≥70 years (p=0.00085), never smokers (p<0.0001), with better baseline Eastern Cooperative Oncology Group-Performance Status (p=0.0127), and had lower prevalence of central nervous system (p=0.0002) and liver metastases (p=0.0395). Univariable analyses showed a significant difference in the median OS across underweight (15.5 months), normal weight (14.6 months), overweight (20.9 months), and obese (16.8 months) patients (log-rank: p=0.045, log rank test for trend: p=0.131), while no difference was found with respect to the median PFS (log-rank for trend: p=0.510). Neither OS nor PFS was significantly associated with baseline BMI on multivariable analysis | ||
| 520 | |a CONCLUSIONS: In contrast to what was observed in the context of chemotherapy-free ICI-based regimens, baseline BMI does not affect clinical outcomes from chemoimmunotherapy combinations in patients with advanced NSCLC | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a immunity | |
| 650 | 4 | |a lung neoplasms | |
| 650 | 4 | |a metabolic networks and pathways | |
| 650 | 4 | |a programmed cell death 1 receptor | |
| 650 | 7 | |a Immune Checkpoint Inhibitors |2 NLM | |
| 700 | 1 | |a Ricciuti, Biagio |e verfasserin |4 aut | |
| 700 | 1 | |a Vaz, Victor R |e verfasserin |4 aut | |
| 700 | 1 | |a Soldato, Davide |e verfasserin |4 aut | |
| 700 | 1 | |a Alessi, Joao V |e verfasserin |4 aut | |
| 700 | 1 | |a Dall'Olio, Filippo G |e verfasserin |4 aut | |
| 700 | 1 | |a Banna, Giuseppe L |e verfasserin |4 aut | |
| 700 | 1 | |a Muthuramalingam, Sethupathi |e verfasserin |4 aut | |
| 700 | 1 | |a Chan, Samuel |e verfasserin |4 aut | |
| 700 | 1 | |a Majem, Margarita |e verfasserin |4 aut | |
| 700 | 1 | |a Piedra, Aida |e verfasserin |4 aut | |
| 700 | 1 | |a Lamberti, Giuseppe |e verfasserin |4 aut | |
| 700 | 1 | |a Andrini, Elisa |e verfasserin |4 aut | |
| 700 | 1 | |a Addeo, Alfredo |e verfasserin |4 aut | |
| 700 | 1 | |a Friedlaender, Alex |e verfasserin |4 aut | |
| 700 | 1 | |a Facchinetti, Francesco |e verfasserin |4 aut | |
| 700 | 1 | |a Gorría, Teresa |e verfasserin |4 aut | |
| 700 | 1 | |a Mezquita, Laura |e verfasserin |4 aut | |
| 700 | 1 | |a Hoton, Delphine |e verfasserin |4 aut | |
| 700 | 1 | |a Valerie, Lacroix |e verfasserin |4 aut | |
| 700 | 1 | |a Nana, Frank Aboubakar |e verfasserin |4 aut | |
| 700 | 1 | |a Artingstall, James |e verfasserin |4 aut | |
| 700 | 1 | |a Comins, Charles |e verfasserin |4 aut | |
| 700 | 1 | |a Di Maio, Massimo |e verfasserin |4 aut | |
| 700 | 1 | |a Caglio, Andrea |e verfasserin |4 aut | |
| 700 | 1 | |a Cave, Judith |e verfasserin |4 aut | |
| 700 | 1 | |a McKenzie, Hayley |e verfasserin |4 aut | |
| 700 | 1 | |a Newsom-Davis, Thomas |e verfasserin |4 aut | |
| 700 | 1 | |a Evans, Joanne S |e verfasserin |4 aut | |
| 700 | 1 | |a Tiseo, Marcello |e verfasserin |4 aut | |
| 700 | 1 | |a D'Alessio, Antonio |e verfasserin |4 aut | |
| 700 | 1 | |a Fulgenzi, Claudia A M |e verfasserin |4 aut | |
| 700 | 1 | |a Besse, Benjamin |e verfasserin |4 aut | |
| 700 | 1 | |a Awad, Mark M |e verfasserin |4 aut | |
| 700 | 1 | |a Pinato, David J |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal for immunotherapy of cancer |d 2013 |g 10(2022), 2 vom: 01. Feb. |w (DE-627)NLM23381065X |x 2051-1426 |7 nnns |
| 773 | 1 | 8 | |g volume:10 |g year:2022 |g number:2 |g day:01 |g month:02 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1136/jitc-2021-004374 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 10 |j 2022 |e 2 |b 01 |c 02 | ||